ECSP11011307A - Comprimidos para terapia de combinacion - Google Patents
Comprimidos para terapia de combinacionInfo
- Publication number
- ECSP11011307A ECSP11011307A EC2011011307A ECSP11011307A ECSP11011307A EC SP11011307 A ECSP11011307 A EC SP11011307A EC 2011011307 A EC2011011307 A EC 2011011307A EC SP11011307 A ECSP11011307 A EC SP11011307A EC SP11011307 A ECSP11011307 A EC SP11011307A
- Authority
- EC
- Ecuador
- Prior art keywords
- tablets
- combination therapy
- formula
- compound
- salt
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona formas farmaceuticas sólidas (por ejemplo comprimidos) que comprende un compuesto de Formula I, un compuesto de Formula II, un compuesto de Formula III y una sal de Formula IV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15065209P | 2009-02-06 | 2009-02-06 | |
| US15065509P | 2009-02-06 | 2009-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011307A true ECSP11011307A (es) | 2011-10-31 |
Family
ID=41722740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011307A ECSP11011307A (es) | 2009-02-06 | 2011-09-06 | Comprimidos para terapia de combinacion |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20100285122A1 (es) |
| EP (1) | EP2393485B1 (es) |
| JP (2) | JP5611242B2 (es) |
| KR (2) | KR101738325B1 (es) |
| CN (1) | CN102307573B (es) |
| AP (1) | AP3250A (es) |
| AR (1) | AR075369A1 (es) |
| AU (1) | AU2010210598B2 (es) |
| BR (1) | BRPI1008664A2 (es) |
| CA (1) | CA2750521A1 (es) |
| CL (1) | CL2011001885A1 (es) |
| CY (1) | CY1116852T1 (es) |
| DK (1) | DK2393485T3 (es) |
| EA (2) | EA030123B1 (es) |
| EC (1) | ECSP11011307A (es) |
| ES (1) | ES2548886T3 (es) |
| HR (1) | HRP20151009T1 (es) |
| HU (1) | HUE025822T2 (es) |
| IL (1) | IL214227A (es) |
| MX (1) | MX2011008289A (es) |
| NZ (1) | NZ594214A (es) |
| PE (1) | PE20110994A1 (es) |
| PL (1) | PL2393485T3 (es) |
| PT (1) | PT2393485E (es) |
| SG (3) | SG173544A1 (es) |
| SI (1) | SI2393485T1 (es) |
| SM (1) | SMT201500266B (es) |
| TW (1) | TWI444367B (es) |
| UY (1) | UY32424A (es) |
| WO (1) | WO2010091197A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2049506T5 (pl) | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| MX2009008935A (es) * | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| MX2010011963A (es) * | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| JP2014500261A (ja) | 2010-11-19 | 2014-01-09 | ギリアード サイエンシーズ， インコーポレイテッド | リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 |
| US20130243833A1 (en) * | 2010-11-29 | 2013-09-19 | Formac Pharmaceuticals N.V. | Compressed formulations of ordered mesoporous silicas |
| EP2729130B1 (en) | 2011-07-07 | 2017-09-06 | Janssen Sciences Ireland UC | Darunavir combination formulations |
| ES2608871T5 (es) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
| AU2013204727A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
| AU2012327170A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
| HK1204980A1 (en) * | 2012-03-01 | 2015-12-11 | Gilead Sciences, Inc. | Spray dried formulations |
| CN103830192A (zh) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法 |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| PT4070788T (pt) | 2015-06-30 | 2023-06-06 | Gilead Sciences Inc | Formulações farmacêuticas |
| WO2017083304A1 (en) | 2015-11-09 | 2017-05-18 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| EP3411378B1 (en) | 2016-02-02 | 2020-03-25 | Sandoz AG | Crystalline forms of tenofovir alafenamide monofumarate |
| WO2022034232A1 (en) * | 2020-08-13 | 2022-02-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Gastro-resistant high-strength formulation containing posaconazole |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA923640B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| SK2662004A3 (sk) | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
| JP3567162B1 (ja) * | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| CN100375742C (zh) * | 2002-11-20 | 2008-03-19 | 日本烟草产业株式会社 | 4-氧代喹啉化合物及其用途 |
| DK1583542T3 (da) | 2003-01-14 | 2008-09-22 | Gilead Sciences Inc | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| RU2008128424A (ru) * | 2005-12-14 | 2010-01-20 | Сипла Лимитед (In) | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы |
| PL2049506T5 (pl) * | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| MX2009008935A (es) * | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
-
2010
- 2010-02-04 EP EP10703766.5A patent/EP2393485B1/en not_active Revoked
- 2010-02-04 BR BRPI1008664A patent/BRPI1008664A2/pt not_active Application Discontinuation
- 2010-02-04 PE PE2011001449A patent/PE20110994A1/es active IP Right Grant
- 2010-02-04 AU AU2010210598A patent/AU2010210598B2/en not_active Ceased
- 2010-02-04 NZ NZ594214A patent/NZ594214A/xx not_active IP Right Cessation
- 2010-02-04 US US12/700,608 patent/US20100285122A1/en not_active Abandoned
- 2010-02-04 HU HUE10703766A patent/HUE025822T2/en unknown
- 2010-02-04 SI SI201031019T patent/SI2393485T1/sl unknown
- 2010-02-04 MX MX2011008289A patent/MX2011008289A/es active IP Right Grant
- 2010-02-04 DK DK10703766.5T patent/DK2393485T3/en active
- 2010-02-04 JP JP2011549268A patent/JP5611242B2/ja not_active Expired - Fee Related
- 2010-02-04 AP AP2011005857A patent/AP3250A/xx active
- 2010-02-04 KR KR1020167020504A patent/KR101738325B1/ko not_active Expired - Fee Related
- 2010-02-04 SG SG2011056306A patent/SG173544A1/en unknown
- 2010-02-04 WO PCT/US2010/023226 patent/WO2010091197A2/en not_active Ceased
- 2010-02-04 EA EA201491658A patent/EA030123B1/ru not_active IP Right Cessation
- 2010-02-04 PT PT107037665T patent/PT2393485E/pt unknown
- 2010-02-04 SG SG10201706215UA patent/SG10201706215UA/en unknown
- 2010-02-04 SG SG2014007744A patent/SG2014007744A/en unknown
- 2010-02-04 HR HRP20151009TT patent/HRP20151009T1/hr unknown
- 2010-02-04 CA CA2750521A patent/CA2750521A1/en not_active Abandoned
- 2010-02-04 CN CN2010800066460A patent/CN102307573B/zh not_active Expired - Fee Related
- 2010-02-04 ES ES10703766.5T patent/ES2548886T3/es active Active
- 2010-02-04 PL PL10703766T patent/PL2393485T3/pl unknown
- 2010-02-04 KR KR1020117020652A patent/KR101645759B1/ko not_active Expired - Fee Related
- 2010-02-04 EA EA201190125A patent/EA021313B1/ru not_active IP Right Cessation
- 2010-02-05 AR ARP100100328A patent/AR075369A1/es unknown
- 2010-02-06 TW TW099103651A patent/TWI444367B/zh not_active IP Right Cessation
- 2010-02-08 UY UY0001032424A patent/UY32424A/es not_active Application Discontinuation
-
2011
- 2011-07-21 IL IL214227A patent/IL214227A/en not_active IP Right Cessation
- 2011-08-05 CL CL2011001885A patent/CL2011001885A1/es unknown
- 2011-09-06 EC EC2011011307A patent/ECSP11011307A/es unknown
-
2014
- 2014-09-02 JP JP2014178005A patent/JP5911927B2/ja active Active
-
2015
- 2015-02-06 US US14/616,563 patent/US20150150810A1/en not_active Abandoned
- 2015-10-26 CY CY20151100953T patent/CY1116852T1/el unknown
- 2015-10-28 SM SM201500266T patent/SMT201500266B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
| CO6511251A2 (es) | Compuestos quimicos | |
| EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
| CL2011001254A1 (es) | Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente a cd38 y al menos melfalan; y su uso para el tratamiento contra el cancer. | |
| SV2011004061A (es) | Aril-piridinas como inhibidores de sintasa de aldosterona | |
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| MX2012006233A (es) | Nuevos compuestos de espiropiperidina. | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| BRPI1008498A2 (pt) | Composto, prodroga do composto, medicamento, e, uso de um composto. | |
| CL2007003138A1 (es) | Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| UY32535A (es) | Métodos e intermediarios para la preparación de agentes farmacéuticos | |
| EA201001710A3 (ru) | Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин | |
| CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| HN2008001723A (es) | Nitrilos espirociclicos como inhibidores de proteasa | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
| EA201490761A1 (ru) | R(+)-n-формилпропаргиламиноиндан | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CR11601A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
| ES2415029R1 (es) | Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24. | |
| EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
| EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол |